{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T14:31:17Z","timestamp":1780410677661,"version":"3.54.1"},"reference-count":32,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2024,9,14]],"date-time":"2024-09-14T00:00:00Z","timestamp":1726272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>The increase in fluoroquinolone (FQ)-resistant Escherichia coli (EC) is a serious global problem. In addition, much of acute uncomplicated cystitis (AUC) cases are caused by EC. FQs have been selected for the treatment of cystitis in outpatients, and there is concern about treatment failure. It is therefore necessary to select appropriate antimicrobials to spare FQs. However, there are few reported effective antimicrobial stewardship programs (ASPs) for outpatients. We aimed to establish the effective ASP for outpatients diagnosed with AUC caused by EC, to spare the use of FQs, and to explore optimal oral antimicrobials for AUC. The study subjects were outpatients treated for AUC caused by extended-spectrum \u03b2-lactamase-non-producing EC (non-ESBL-EC). Based on the antibiogram results, we recommended cefaclor (CCL) as the initial treatment for AUC, and educated clinical pharmacists who also worked together to advocate for CCL or cephalexin (CEX) prescriptions. FQ usages decreased, and cephalosporin (Ceph) prescriptions increased in all medical departments. The Ceph group (n = 114; CCL = 60, CEX = 54) in the non-FQ group had fewer treatment failures than the FQ group (n = 86) (12.3% vs. 31.4%). Cephs, including CCL and CEX, were effective treatments for AUC caused by non-ESBL-EC. Antimicrobial selection based on antibiogram results and the practice of an ASP in collaboration with clinical pharmacists were useful for optimizing antimicrobial therapy in outpatients.<\/jats:p>","DOI":"10.3390\/antibiotics13090886","type":"journal-article","created":{"date-parts":[[2024,9,18]],"date-time":"2024-09-18T01:52:31Z","timestamp":1726624351000},"page":"886","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Establishment of an Antimicrobial Stewardship Program to Spare the Use of Oral Fluoroquinolones for Acute Uncomplicated Cystitis in Outpatients"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8056-5535","authenticated-orcid":false,"given":"Tomoyuki","family":"Kato","sequence":"first","affiliation":[{"name":"Department of Pharmacy, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"},{"name":"Department of Infection Control, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8085-4940","authenticated-orcid":false,"given":"Masayuki","family":"Nagasawa","sequence":"additional","affiliation":[{"name":"Department of Infection Control, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"},{"name":"Department of Pediatrics, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7867-9381","authenticated-orcid":false,"given":"Ippei","family":"Tanaka","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuka","family":"Seyama","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8310-3736","authenticated-orcid":false,"given":"Reiko","family":"Sekikawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiori","family":"Yamada","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Ishikawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kento","family":"Kitajima","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Musashino Red Cross Hospital, 1-26-1, Kyonancho, Musashino-shi, Tokyo 180-8610, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,9,14]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1021\/bi5000564","article-title":"Mechanism of quinolone action and resistance","volume":"53","author":"Katie","year":"2014","journal-title":"Biochemistry"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"233S","DOI":"10.1592\/phco.21.16.233S.33992","article-title":"Pharmacokinetics and pharmacodynamics of fluoroquinolones","volume":"21","author":"Rodvold","year":"2001","journal-title":"Pharmacotherapy"},{"key":"ref_3","first-page":"311","article-title":"In vitro activity of sitafloxacin against clinical isolates in 2012","volume":"66","author":"Amano","year":"2013","journal-title":"Jpn. J. Antibiot."},{"key":"ref_4","unstructured":"(2024, July 07). Antimicrobial Resistance: Tackling a Crisis for the Health and Wealth of Nations. The Review on Antimicrobial Resistance Chaired by Jim O\u2019Neill December 2014. Available online: https:\/\/amr-review.org\/sites\/default\/files\/AMR%20Review%20Paper%20-%20Tackling%20a%20crisis%20for%20the%20health%20and%20wealth%20of%20nations_1.pdf."},{"key":"ref_5","unstructured":"Antimicrobial Resistance Collaborators (2022). Global burden of bacterial antimicrobial resistance in 2019: A systematic analysis. Lancet, 399, 629\u2013655."},{"key":"ref_6","unstructured":"The Government of Japan (2024, July 07). National Action Plan on Antimicrobial Resistance (AMR) 2016\u20132020. Available online: https:\/\/www.mhlw.go.jp\/file\/06-Seisakujouhou-10900000-Kenkoukyoku\/0000138942.pdf."},{"key":"ref_7","unstructured":"The Government of Japan (2024, July 07). National Action Plan on Antimicrobial Resistance (AMR) 2023\u20132027. Available online: https:\/\/www.mhlw.go.jp\/content\/10900000\/001096228.pdf."},{"key":"ref_8","first-page":"27","article-title":"Urinary tract infection risk factors and gender","volume":"3","author":"Harrington","year":"2000","journal-title":"J. Gend. Specif. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1093\/cid\/ciq257","article-title":"International clinical practice guidelines for the treatment of acute uncomplicated cystitis and pyelonephritis in women: A 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases","volume":"52","author":"Gupta","year":"2011","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1016\/j.juro.2013.10.064","article-title":"A comparison of inpatient versus outpatient resistance patterns of pediatric urinary tract infection","volume":"191","author":"Saperston","year":"2014","journal-title":"J. Urol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1016\/S1473-3099(20)30121-3","article-title":"Reappraisal of the treatment duration of antibiotic regimens for acute uncomplicated cystitis in adult women: A systematic review and network meta-analysis of 61 randomised clinical trials","volume":"20","author":"Kim","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.jgar.2016.07.002","article-title":"Japanese antimicrobial consumption surveillance: First report on oral and parenteral antimicrobial consumption in Japan (2009\u20132013)","volume":"7","author":"Muraki","year":"2016","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"ofaa513","DOI":"10.1093\/ofid\/ofaa513","article-title":"Antimicrobial Stewardship Practice in the Ambulatory Setting From a National Cohort","volume":"7","author":"Eudy","year":"2020","journal-title":"Open Forum Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jiac.2024.01.011","article-title":"Third nationwide surveillance of bacterial pathogens in patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2020 and 2021: Antimicrobial susceptibility of Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus","volume":"30","author":"Wada","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1128\/AAC.00665-08","article-title":"Mechanisms accounting for fluoroquinolone resistance in Escherichia coli clinical isolates","volume":"53","author":"Sonia","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1016\/j.meegid.2011.06.001","article-title":"Genetic evolution and clinical impact in extended-spectrum \u03b2-lactamase-producing Escherichia coli and Klebsiella pneumoniae","volume":"11","author":"Chong","year":"2011","journal-title":"Infect. Genet. Evol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1093\/jac\/dkx146","article-title":"Global epidemiology of CTX-M \u03b2-lactamases: Temporal and geographical shifts in genotype","volume":"72","author":"Edward","year":"2017","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/j.jmii.2011.12.019","article-title":"Correlation between levofloxacin consumption and the incidence of nosocomial infections due to fluoroquinolone-resistant Escherichia coli","volume":"49","author":"Wu","year":"2016","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Kim, J.Y., Yum, Y., Joo, H.J., An, H., Yoon, Y.K., Kim, J.H., and Sohn, J.W. (2021). Impact of antibiotic usage on extended-spectrum \u03b2-lactamase producing Escherichia coli prevalence. Sci. Rep., 11.","DOI":"10.1038\/s41598-021-91332-x"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1093\/cid\/ciac268","article-title":"Infectious Diseases Society of America 2022 Guidance on the Treatment of Extended-Spectrum \u03b2-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)","volume":"75","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1093\/cid\/ciab1013","article-title":"Infectious Diseases Society of America Guidance on the Treatment of AmpC \u03b2-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections","volume":"74","author":"Tamma","year":"2022","journal-title":"Clin. Infect. Dis."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.jiac.2020.10.010","article-title":"The effectiveness of prescription support and treatment reporting system on the appropriate usage of oral third-generation cephalosporins","volume":"27","author":"Kato","year":"2021","journal-title":"J. Infect. Chemother."},{"key":"ref_23","unstructured":"Tuberculosis and Infectious Diseases Control Division (2024, July 07). Health Service Bureau, Ministry of Health, Labour and Welfare. Guidance for Appropriate Use of Antimicrobial Agents, 3rd ed., Available online: https:\/\/www.mhlw.go.jp\/content\/10900000\/001265278.pdf."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"ofad459","DOI":"10.1093\/ofid\/ofad459","article-title":"Impact of Fluoroquinolone Susceptibility Suppression on Discharge Prescribing for Acute Uncomplicated Cystitis","volume":"10","author":"Hayden","year":"2023","journal-title":"Open Forum Infect. Dis."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1001\/jamainternmed.2023.2749","article-title":"A Statewide Quality Initiative to Reduce Unnecessary Antibiotic Treatment of Asymptomatic Bacteriuria","volume":"183","author":"Vaughn","year":"2023","journal-title":"JAMA Intern. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1001\/jamainternmed.2018.4204","article-title":"Effect of Increased Daily Water Intake in Premenopausal Women With Recurrent Urinary Tract Infections: A Randomized Clinical Trial","volume":"178","author":"Hooton","year":"2018","journal-title":"JAMA Intern. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.jiac.2017.02.002","article-title":"JAID\/JSC Guidelines for Clinical Management of Infectious Disease 2015\u2014Urinary tract infection\/male genital infection","volume":"23","author":"Yamamoto","year":"2017","journal-title":"J. Infect. Chemother."},{"key":"ref_28","unstructured":"WHO (2024, July 07). Antibiotic Categorization. Available online: https:\/\/aware.essentialmeds.org\/groups."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1197\/jamia.M1299","article-title":"Development of a clinical data Warehouse for hospital infection control","volume":"10","author":"Mary","year":"2003","journal-title":"J. Am. Med. Inform. Assoc."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.jiac.2016.07.018","article-title":"Japanese guideline for clinical research of antimicrobial agents on urogenital infections: Second edition","volume":"22","author":"Yasuda","year":"2016","journal-title":"J. Infect. Chemother."},{"key":"ref_31","unstructured":"(2014). Analysis and Presentation of Cumulative Antimicrobial Susceptibility Test Data; Approved Guideline\u2013Fourth Edition (Standard No. CLSI Document M39-A4)."},{"key":"ref_32","unstructured":"AMR Clinical Reference Center (2024, July 07). Guidelines for Create Antibiogram. Available online: https:\/\/amr.ncgm.go.jp\/pdf\/201904_antibaiogram_guideline.pdf."}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/9\/886\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T15:56:13Z","timestamp":1760111773000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/13\/9\/886"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,14]]},"references-count":32,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2024,9]]}},"alternative-id":["antibiotics13090886"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics13090886","relation":{},"ISSN":["2079-6382"],"issn-type":[{"value":"2079-6382","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,14]]}}}